|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 奥法木单抗>> 市场分析报告 |
奥法木单抗市场分析报告 |
|
Ofatumumab Market, Global Outlook and Forecast 2022-2028 ... 2023-2028 ($ Millions) & (Kg) Global Ofatumumab Market Segment Percentages, by Type ... 2023-2028 ($ Millions) & (Kg) Global Ofatumumab Market Segment Percentages, by Application ... , 2021 (%) Chemical Pharmaceutical Global Ofatumumab Market, By Region and Country ... Global Ofatumumab Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 ... launches or approvals. Market Segmentation Ofatumumab market is split by Type and ... of 15 chapters: Chapter 1, to describe Ofatumumab product scope, market overview, ... and industry chain of Ofatumumab. Chapter 14 and 15, to describe Ofatumumab sales channel, ... Global Ofatumumab Market Status, Trends and COVID-19 Impact Report 2022 ... percent in 2022. According to our research on Ofatumumab market and global economic ... environment, we published the Global Ofatumumab Market Status, Trends and COVID ... provides a comprehensive analysis of the global Ofatumumab market , This Report covers ... Global Ofatumumab Production, Demand and Key Producers, 2022-2028 ... well as details the characteristics of Ofatumumab that contribute to its increasing ... manufacturers and share Global Ofatumumab production by manufacturer, production, price ... , production locations, products portfolio, Ofatumumab revenue, sales, average price ... Global Ofatumumab Market Research Report 2025(Status and Outlook) ... the competitive landscape of the global Ofatumumab market. It offers detailed profiles ... their presence in the Ofatumumab market. Global Ofatumumab Market: Market Segmentation ... of value In-depth analysis of the Ofatumumab Market Overview of the regional ... Global Ofatumumab Market Growth 2025-2031 The report requires updating with new data and is sent in 48 hours after order is placed. The global Medical Vacuum Regulator market size is predicted to grow from US$ 166 million in 2025 to US$ 235 million in 2031; it is expected to grow at a CAGR of 6.0% ... Genmab A/S Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... the Phase III program with ofatumumab to treat rheumatoid arthritis (RA). AlgoNomics NV has ... plc to co-develop and commercialize Arzerra (ofatumumab). History Genmab AS was founded in 1999. Therapy Class Overview: Rituximab biosimilar Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other ... CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. “CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non- ... Anti-CD20 Monoclonal Antibodies: Market Research Report This report analyzes the Global market for Anti-CD20 Monoclonal Antibodies in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 38 companies including many key and niche players such as Bayer ... Global Cancer Immunotherapy Market Analysis & Forecast to 2022 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer ... Multiple Sclerosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... fumarate, fingolimod, monomethyl fumarate, ofatumumab, ozanimod, ponesimod, siponimod, ... enhances tolerability. Trends focus on innovation. Ofatumumab: Expected at 3% to 4%, it targets B-cells, growing ... giant, Roche advances ofatumumab. Bayer: A German firm, ... CLL [2017] ... ) Gazyva/Gazyvaro (obinutuzumab; Roche) Arzerra (ofatumumab; Novartis) Imbruvica (ibrutinib; Janssen Biotech ... Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Market Forecast-2028 This report can be delivered to the clients within 7-10 Business Days DelveInsight’s ‘Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted ... Global Neurodegenerative Disorder Therapeutics Market: Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030 Hard copy option is available on any of the options above at an additional charge of $500. Please email us at Rheumatoid Arthritis Therapeutics: Market Research Report This report analyzes the worldwide markets for Rheumatoid Arthritis Therapeutics in US$ Million.The report provides separate comprehensive analytics for US, Japan, Europe, Latin America and Rest of World. Annual forecasts are provided for each region for ... Cancer Monoclonal Antibodies Market to 2015 Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more ... Cancer Monoclonal Antibodies Market Forecast to 2017 Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical ... US Blood Cancer Drug Market & Pipeline Analysis 2015 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood ... Market Access Impact (EU5) [CLL] ... into 5 Leading CLL Drugs Arzerra (ofatumumab; Novartis/Genmab) Gazyvaro (obinutuzumab; Roche ... |